Registry name: National Food and Drug Surveillance Institute (INVIMA)
Country: Colombia
Year established: 2012
Points of interest:
- Clinical trials in Colombia must be reported to INVIMA
- In 2012, INVIMA was restructured to take on additional responsibilities for the country’s public health, including increased transparency and surveillance measures
- Protocol registration for all interventional clinical trials occurring in Colombia are mandatory, in the Spanish language
- The principal clinical trial researcher must submit written summaries covering the status of the study to a research ethics committee at least once a year
- The researcher must notify the INVIMA of any significant change that affects the conduct of the trial
- Regardless of the study’s outcomes, the principal researcher is responsible for disseminating the study data is disseminated among the scientific community
- Under the Colombian Data Privacy Law (1581/2012), clinical trial data is considered a “special data category” because it encompasses personal health data. As such, the researchers must obtain written consent from subjects.
Related transparency research/articles:
- Clinical trials in Colombia
- Active clinical trials in Colombia
- Colombia promotes itself as a destination for clinical research
- Preclinical and clinical trial requirements: Colombia
- Colombia reduces clinical trial evaluation and approval processes to 60
TrialAssure® Registry can automate the disclosure of clinical trial results for the National Food and Drug Surveillance Institute (INVIMA). For questions or a free demo, fill out this form.